Why technology standards are critical for Quantum-Safe Security

Safeguard Insights

November 8, 2010

Eli Lilly Agrees to Acquire Safeguard Scientifics Partner Company Avid Radiopharmaceuticals

For the second time in as many weeks, I am pleased to announce that a major player in the pharmaceutical industry has recognized the value…

Posted by Peter J. Boni

October 22, 2010

Partner Company Clarient (Nasdaq: CLRT) to be Acquired by GE Healthcare for $587 Million

At Safeguard Scientifics, our strategy is to provide growth capital for entrepreneurial and innovative life sciences and technology companies, build value in those companies and…

Posted by Peter J. Boni

October 20, 2010

Third Quarter 2010 Trends in Venture Capital

According to the latest MoneyTree survey conducted by PricewaterhouseCoopers and the National Venture Capital Association, venture capital investing in the third quarter of 2010 was…

Posted by Peter J. Boni

September 10, 2010

Advancements in Diagnostics

Advances in the life sciences will continue to have a far-reaching impact on virtually every aspect of our society. There is an abundance of companies…

Posted by James A. Datin

July 14, 2010

Video: James A. Datin Talks About Safeguard Scientifics’ Life Sciences Strategy

James A. Datin, Executive Vice President and Managing Director of Life Sciences Group at Safeguard Scientifics, discusses his thoughts on the opportunities in life sciences…

Posted by John E. Shave III

July 12, 2010

Bloomberg Businessweek says Avid likely to Beat GE, Bayer to Market

On the eve of the International Conference on Alzheimer’s Disease (ICAD), Bloomberg Businessweek’s Elizabeth Lopatto and Kanoko Matsuyama reported that Avid Radiopharmaceuticals, Inc., a Safeguard…

Posted by James A. Datin

May 21, 2010

Diagnostic Imaging Continues to Garner Investor Interest

On the heels of the BIO International Convention, I came across this piece by FierceBiotech’s Maureen Martino highlighting a panel of biotech VCs who made…

Posted by James A. Datin

April 15, 2010

Avid Radiopharmaceuticals Announces Positive Interim Results from Phase III Clinical Trial of Amyloid Imaging Agent Florbetapir F18

Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis…

Posted by Peter J. Boni

March 31, 2010

Avid Radiopharmaceuticals Making Strides Toward Clinical Trial Milestone

I frequently attribute Safeguard Scientifics’ success to our disciplined strategy built on five strategic themes, which we refer to as M2C3. We leverage these themes…

Posted by Peter J. Boni

Content